Kisqali (ribociclib) - Novartis
Kisqali: "The P value of 0.00455 crossed the prespecified boundary to claim superior efficacy (P < 0.01129)"; Advanced breast cancer (Novartis) - Oct 14, 2019 - Kisqali MONALEESA-3 ESMO Data Investor Call 
P3 data
https://www.novartis.com/sites/www.novartis.com/files/2019-10-novartis-esmo-investor-call-presentation.pdf
 
Oct 14, 2019
 
 
613ce793-763c-4052-a12c-05f71c603843.jpg

4d1488db-2497-4ceb-b9f5-1d0acd8b8503.jpg